Turn Therapeutics Inc. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how Turn Therapeutics performed this year. My goal is to cut through the corporate talk and give you the facts you need to decide if this company belongs in your portfolio.

1. What does this company do?

Turn Therapeutics focuses on specialized skin and wound treatments. Their lead product, GX-03, is a cream for eczema, nail fungus, and other skin conditions. It does not contain steroids or antibiotics. They also use a technology called PermaFusion®, which stabilizes medications to help them last longer. Essentially, they aim to improve existing treatments to reduce the need for systemic antibiotics.

2. How are they performing?

The company is currently in the research phase and does not yet generate steady revenue from product sales. Their business model relies on licensing their formulas to larger pharmaceutical companies.

Key Progress:

• The Pipeline: They are currently testing GX-03. They expect to release Phase 3 trial results in early 2026, which are essential for FDA approval.
• Strategic Partnerships: They have a deal with Medline Industries, LP, a major medical distributor. Medline has the rights to sell Turn’s antimicrobial gauze, providing a path to market without the need for an internal sales team.

3. Major wins and challenges

• The Big Win: They hold 26 patents in the U.S. and abroad. These protect their "secret sauce" and PermaFusion® technology until at least 2038.
• The Reality Check: This is a lean operation with only two full-time employees. They rely entirely on outside contractors for research, legal, and administrative work.
• Leadership & Control: CEO Bradley Burnam owns approximately 54% of the company. He holds veto power over major decisions, including mergers and hiring.

4. Financial health and risks

This is a high-risk investment that requires significant capital.

• Operating Costs: Operating costs increased from $1.8 million in 2024 to $5.9 million in 2025, largely due to the costs associated with becoming a public company.
• The Cash Situation: At the end of 2025, the company held approximately $5.08 million in cash. Management estimates this will sustain operations until the third quarter of 2026. They require roughly $60–$65 million to complete their clinical trials.
• Dilution Risk: To bridge their funding gap, the company plans to sell up to $85 million in new stock. Issuing these new shares will reduce your ownership percentage and the value of your current shares.

5. Future outlook

Turn is in a high-stakes phase. Their success depends entirely on passing FDA trials and the commercial success of their partners. Because they face a significant funding gap and must rely on selling new shares to stay in business, the path to profitability remains narrow and uncertain.

Investor Takeaway: Before deciding, ask yourself if you are comfortable with a company that has a single-person majority control, relies heavily on external contractors, and faces a multi-million dollar funding requirement before it can prove its product works. This is a speculative play where success is tied to specific clinical milestones in 2026.